OTC FILING WATCH · LIVEOfficial-source OTC filing intelligence
AUTOMATED SEC FILING DILIGENCE BRIEF
PUBLIC-RECORD DELIVERY

Nuo Therapeutics, Inc.

CIK 0001091596Ticker AURXSEC observed OTC

Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.

Open issuer dossier
Reporting & material events73

captured official filings

Registration & offering1

captured official filing

Ownership80

captured official filings

Governance6

captured official filings

WHAT THIS AUTOMATES

One evidence index instead of a manual filing hunt.

It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.

PROFESSIONAL DELIVERY LAYER

What teams can pay to automate next.

Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.

MACHINE-DETECTED FILING CHANGE RADAR

Public registration text delta

Comparing S-1/A filed 2017-06-21 with S-1/A filed 2017-06-30.

Earlier SEC filingLatest SEC filing
429latest comparable sentences
19new-text candidates
24prior-text candidates not found

Tracked-term count changes

Counts are navigation signals, not conclusions. Open both official filings to determine materiality.

  • No tracked keyword-count change was detected in the cached plain-text excerpts.

Candidate disclosure excerpts

Only sentence-level additions or removals containing tracked diligence terms are shown. These are reading cues, not materiality findings.

New in latest filing
  • Preliminary Prospectus Subject to Completion Dated June 30 , 2017 2,100,000 Shares of Common Stock Nuo Therapeutics, Inc. is offering 2,100,000 shares of our common stock to purchasers in this offering.
  • The Offering Number of shares of common stock we are offering 2,100,000 shares (2,415,000 shares if the underwriters exercise their over-allotment option in full).
  • Common stock to be outstanding after this offering if aggregate gross proceeds are less than $10.5 million 6,070,845 shares (6,385,845 if the underwriters exercise their over-allotment option in full).
Present in earlier filing, not found in latest
  • Preliminary Prospectus Subject to Completion Dated June 20 , 2017 2,100,000 Shares of Common Stock Nuo Therapeutics, Inc. is offering 2,100,000 shares of our common stock to purchasers in this offering.
  • The Offering Number of shares of common stock we are offering 2,100,000 shares (2,415,000 shares if the underwriter exercises its over-allotment option in full).
  • Common stock to be outstanding after this offering if aggregate gross proceeds are less than $10.5 million 6,070,845 shares (6,385,845 if the underwriter exercises its over-allotment option in full).

Method: readable plain text is extracted from two official SEC HTML filings, then compared at sentence and tracked-term level. Formatting, exhibit differences and boilerplate may create false positives. This radar is not legal advice, a disclosure completeness opinion or a transaction recommendation.

DOWNLOAD EDITION

Save a project-ready issuer record.

US$29 one time. No subscription and no account. You receive the current printable Evidence Snapshot in this browser immediately after verified payment.

  • Source-linked filing chronology and registration path
  • Machine-detected amendment and tracked-term change view
  • Official-source index for project-file archiving and downloadable CSV export

Secure checkout by PayPal.

AUTOMATED EVIDENCE SNAPSHOT

Save this source-linked record

Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.

Unlock download · US$29
OFFICIAL SEC SUBMISSIONS

Captured filing chronology

Open Evidence Snapshot →
  1. 4
    OwnershipOpen SEC filing →
  2. 4
    OwnershipOpen SEC filing →
  3. 4
    OwnershipOpen SEC filing →
  4. 4
    OwnershipOpen SEC filing →
  5. 4
    OwnershipOpen SEC filing →
  6. 4
    OwnershipOpen SEC filing →
  7. 8-K
    Reporting & material eventsOpen SEC filing →
  8. 4
    OwnershipOpen SEC filing →
  9. 8-K
    Reporting & material eventsOpen SEC filing →
  10. 10-Q
    Reporting & material eventsOpen SEC filing →
  11. 10-K
    Reporting & material eventsOpen SEC filing →
  12. 4
    OwnershipOpen SEC filing →
  13. 8-K
    Reporting & material eventsOpen SEC filing →
  14. 4
    OwnershipOpen SEC filing →
  15. 4
    OwnershipOpen SEC filing →
  16. 8-K
    Reporting & material eventsOpen SEC filing →
  17. 4
    OwnershipOpen SEC filing →
  18. 4
    OwnershipOpen SEC filing →
  19. 10-Q
    Reporting & material eventsOpen SEC filing →
  20. DEF 14A
    GovernanceOpen SEC filing →
  21. 8-K
    Reporting & material eventsOpen SEC filing →
  22. 4
    OwnershipOpen SEC filing →
  23. 4
    OwnershipOpen SEC filing →
  24. 4
    OwnershipOpen SEC filing →
  25. 4
    OwnershipOpen SEC filing →
  26. 4
    OwnershipOpen SEC filing →
  27. 4
    OwnershipOpen SEC filing →
  28. 10-Q
    Reporting & material eventsOpen SEC filing →
  29. 8-K
    Reporting & material eventsOpen SEC filing →
  30. EFFECT
    Registration & offeringOpen SEC filing →
  31. 10-Q
    Reporting & material eventsOpen SEC filing →
  32. 10-K
    Reporting & material eventsOpen SEC filing →
  33. 4
    OwnershipOpen SEC filing →
  34. SC 13G/A
    OwnershipOpen SEC filing →
  35. 10-Q
    Reporting & material eventsOpen SEC filing →
  36. SC 13G/A
    OwnershipOpen SEC filing →
  37. 4
    OwnershipOpen SEC filing →
  38. 8-K
    Reporting & material eventsOpen SEC filing →
  39. 10-Q
    Reporting & material eventsOpen SEC filing →
  40. 4
    OwnershipOpen SEC filing →
  41. 4
    OwnershipOpen SEC filing →
  42. 4
    OwnershipOpen SEC filing →
  43. 8-K
    Reporting & material eventsOpen SEC filing →
  44. 8-K
    Reporting & material eventsOpen SEC filing →
  45. 4
    OwnershipOpen SEC filing →
  46. 4
    OwnershipOpen SEC filing →
  47. 4
    OwnershipOpen SEC filing →
  48. 8-K
    Reporting & material eventsOpen SEC filing →
  49. 10-Q
    Reporting & material eventsOpen SEC filing →
  50. 10-K
    Reporting & material eventsOpen SEC filing →
  51. 8-K
    Reporting & material eventsOpen SEC filing →
  52. SC 13G
    OwnershipOpen SEC filing →
  53. SC 13G/A
    OwnershipOpen SEC filing →
  54. SC 13D/A
    OwnershipOpen SEC filing →
  55. 4
    OwnershipOpen SEC filing →
  56. 4
    OwnershipOpen SEC filing →
  57. 4
    OwnershipOpen SEC filing →
  58. 8-K
    Reporting & material eventsOpen SEC filing →
  59. 10-Q
    Reporting & material eventsOpen SEC filing →
  60. 10-Q
    Reporting & material eventsOpen SEC filing →
Evidence boundary

Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.